Selected Posters and Abstracts
Efavirenz (Sustiva) [NNRTI]
•[P11] Effectiveness of didanosine, lamivudine, efavirenz and zidovudine, lamivudina, efavirenz in naive HIV-infected patients from the Spanish VACH cohort (QuoVideS study) 
Ignacio Suarez-Lozano and others.
•[P32] Simplification to efavirenz + abacavir/lamivudine (Kivexa) in previously suppressed HIV-infected patients compared with other conventional regimens of 2 nucleosides + efavirenz: 6-months of follow-up
Patricia Echeverria and others.
•[P260] Nevirapine vs. efavirenz based treatment in ART naive patients in India: a comparison of immunological response 
Kadappa Satish and others.
•[P365] TDM of efavirenz as a tool of adherence in HIV-infected children
R Rosso and others.
•[P281] Efavirenz induction of the UGT-1A1 reduces atazanavir-induced hyperbilirubinemia 
E Mossdorf and others.
•[P286] Pharmacokinetics of lopinavir and ritonavir after multiple dose administration of lopinavir/ritonavir tablet co-administered with efavirenz
C E Klein and others.
•[P59] Final safety and efficacy analysis of a randomised pilot study evaluating early versus late switch from efavirenz to nevirapine as part of HAART: the BI Switch Study
M Youle and others.
•[PL2.3] Induction-maintenance antiretroviral therapy with Trizivir plus either efavirenz or lopinavir/r: results of a multicentre randomized clinical trial at 72 weeks
J Mallolas and others.
•[P272] Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz concentrations
Else and others.
•[P7] Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in naive patients: a multicentre, randomized study  
P Echeverria and others.
•[P282] Pharmacogenetic factors associated to virological failure and/or CNS toxicity in patients treated with efavirenz 
S Rodriguez-Novoa and others.
•[P216] Genotypic resistance in HIV+ naive patients enrolled in a 96-week randomized trial comparing abacavir (ABC) vs. stavudine (d4T), both combined with lamivudine/efavirenz (3TC/EFV)
E Ferrer and others.
•[P120] Switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) resulted in continued virologic suppression and improvement in lipoatrophy through 2 years in HIV-infected patients
J VR Madruga and others.
•[P54] Simplification from protease inhibitor (PI) to efavirenz (EFV) based HAART in virologically suppressed HIV-infected subjects
C Cohen and others.
•[P4] Efavirenz (EFV) vs. Lopinavit/ritonavir (LPV/r)-based combined antiretroviral therapy in antiretroviral-naive HIV-infected patients from the Spanish VACH cohort: the SUSKA study
P Domingo and others.
•[P6] Efficacy and safety of Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz (EFV) compared to fixed dose Zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naive patients
A Pozniak and others.
•[P9] Similar virologic and immunologic response to efavirenz or lopinavir/ritonavir-based HAART in a large cohort of antiretroviral-naïve patients with advanced HIV infection
F Pulido and others.
•[P109] Nevirapine vs efavirenz in 742 patients: the liver toxicity of nevirapine is not linked to the female sex and a baseline CD4 count above 250 cells/L
R Manfredi and Leonardo Calza.
•[P152] The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) through 5 years in antiretroviral-naive patients
I Cassetti and others.
 

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva
Norvir
Prezista
Reyataz
Viracept

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor
Sustiva
Viramune

Entry Inhibitors
 Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada